[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100407991":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":31,"locations":41,"responsibleParty":58,"collaborators":61,"id":64,"slug":20,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":20,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":20,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":87,"overallStatus":43,"whyStopped":20,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"The First Affiliated Hospital with Nanjing Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"hAMSC Treatment Group","EXPERIMENTAL","hAMSC treatment regimen: (1) Intravenous infusion: 1.0×10⁶ cells\u002Fkg administered three times consecutively at weeks 1, 2, and 4, followed by once every 4 weeks for a total of 8 doses (6 months). (2) Local injection: 2.0×10⁴ cells\u002Fcm² of wound area, administered concurrently. Treatment may be terminated earlier or extended based on clinical condition.",[13],"Biological: Human amniotic-derived mesenchymal stem cells",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","Human amniotic-derived mesenchymal stem cells","(1) Intravenous infusion: 1.0×10⁶ cells\u002Fkg administered three times consecutively at weeks 1, 2, and 4, followed by once every 4 weeks for a total of 8 doses (6 months). (2) Local injection: 2.0×10⁴ cells\u002Fcm² of wound area, administered concurrently. Treatment may be terminated earlier or extended based on clinical condition.",[9],null,[22,26,29],{"name":23,"affiliation":24,"role":25},"Ningning Wang, Professor","The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital","PRINCIPAL_INVESTIGATOR",{"name":27,"affiliation":24,"role":28},"Jiayin Liu, Professor","STUDY_DIRECTOR",{"name":30,"affiliation":24,"role":25},"Lianju Qin",[32,37],{"name":23,"role":33,"phone":34,"phoneExt":35,"email":36},"CONTACT","86-013813821064","+8613813821064","wangnn@njmu.edu.cn",{"name":38,"role":33,"phone":39,"phoneExt":20,"email":40},"Lianju Qin, Professor","86-018012923584","ljqin@njmu.edu.cn",[42],{"facility":24,"status":43,"city":44,"state":45,"zip":46,"country":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"RECRUITING","Nanjing","Jiangsu","210029","China",{"type":49,"coordinates":50},"Point",[51,52],118.77778,32.06167,{"lat":52,"lon":51},[55,57],{"name":23,"role":33,"phone":56,"phoneExt":20,"email":36},"+86-013813821064",{"name":38,"role":33,"phone":39,"phoneExt":20,"email":40},{"type":25,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Ningning Wang","Professor",[62],{"name":63,"class":6},"Westlake University","100407991",false,"NCT04592640","Human Amniotic-Derived Mesenchymal Stem Cell Therapy for Calciphylaxis","Effects of Human Amniotic-derived Mesenchymal Stem Cells (hAMSCs) on Calciphylaxis Patients: An Open-Label Single-Arm Study","Inclusion Criteria:\n\n1. 18-75 years old.\n2. Clinical diagnosis of calciphylaxis, including patients with chronic kidney disease who did not or had regular dialysis (hemodialysis or peritoneal dialysis).\n3. All subjects signed informed consent.\n\nExclusion criteria:\n\n1. Patients who refuse to sign informed consent.\n2. Patients with malignant tumors or severe psychiatric disorders, or an expected survival time of less than 6 months.\n3. Pregnant or lactating women of childbearing age.\n4. Participation in another clinical trial with an experimental drug within 90 days prior the inclusion.","ALL","18 Years","75 Years",{"count":74,"type":75},9,"ESTIMATED","INTERVENTIONAL",[78],"EARLY_PHASE1","Treatment for Calciphylaxis Patients with Human Amniotic-derived Mesenchymal Stem Cells",[81,82,83,84,85,86],"Chronic Kidney Diseases","Calciphylaxis","Calcific Uremic Arteriolopathy","Treatment","Safety","Efficacy",[81,82,83,88,89,85,86],"Human Amniotic-derived Mesenchymal Stem Cells","Rare disease (ORPHA280062)","2026-03-02",{"date":92,"type":93},"2026-03-04","ACTUAL",{"date":95,"type":93},"2018-09-17",{"date":97,"type":75},"2028-09-17",{"name":5,"class":6},1]